Gene Therapy CSIR NET Life Science | for Bsc Nursing 2nd Year | CSIR NET Applied Biology
Why It Matters
Gene therapy promises cures for genetic and otherwise untreatable diseases, but its experimental status and safety challenges mean that progress will directly shape the next wave of biotech investment and regulatory frameworks.
Key Takeaways
- •Ex vivo gene therapy expands cells outside body before re‑implantation.
- •In vivo approach delivers vectors directly, simplifying treatment logistics.
- •Vector choice (viral, liposome, naked DNA) impacts efficiency and safety.
- •Immune reactions and off‑target integration remain major safety hurdles.
- •Current clinical results are mixed; gene therapy remains experimental.
Summary
The video provides a concise overview of gene therapy, contrasting the two principal delivery strategies—ex vivo (Xvivo) and in vivo. Ex vivo therapy harvests patient cells, modifies them with a therapeutic gene in culture, and then re‑infuses the corrected cells, while in vivo therapy injects the gene‑carrying vector directly into the patient’s body. Key insights include the definition of gene therapy as the insertion, alteration, or removal of genes to treat disease, the variety of vectors used (viral particles, liposomes, naked DNA), and the procedural steps for each approach. Ex vivo methods allow real‑time monitoring of gene transfer and reduce immune exposure, whereas in vivo methods are simpler but risk off‑target delivery and immune reactions. The presenter cites concrete examples such as retroviral delivery of a functional ADA gene to treat severe combined immunodeficiency, and experimental applications in cystic fibrosis, various cancers, and HIV. He also explains the use of reporter genes to verify successful integration and expression within host cells. Despite these advances, the speaker emphasizes that gene therapy remains largely experimental, with mixed clinical outcomes, limited standardized protocols, and significant safety concerns—particularly immune responses and challenges targeting non‑dividing cells. The technology’s future hinges on overcoming these hurdles to become a reliable therapeutic modality.
Comments
Want to join the conversation?
Loading comments...